The Cost of Non-Compliance in Australia’s Medicinal Cannabis Industry
Australia’s medicinal cannabis industry has experienced remarkable growth over the past decade. As the market matures, it’s important now more than ever for stakeholders to continue to prioritise regulatory compliance for both improved patient outcomes and safety.
Recent enforcement action by the Therapeutic Goods Administration (Therapeutic Goods Administration, 2026) demonstrates that businesses failing to comply with regulatory legislation face far more than financial penalties, with enforcement action potentially resulting in reputational damage, regulatory intervention, operational disruption and the loss of trust from patients, healthcare professionals and commercial partners.
Compliance Is More Than Avoiding Fines
With compliance being a top priority for medicinal cannabis businesses, solid frameworks are essential to underpin sustainable business growth. For medicinal cannabis businesses, compliance extends across:
Advertising and promotional activities
Therapeutic Goods Administration (TGA) requirements
Product claims and medical education
Healthcare practitioner engagement
Privacy and patient information
Distribution and wholesale
Pharmacovigilance and adverse event (AE) reporting
Internal governance and quality systems
Weaknesses in any of these areas can expose a business to significant risk.
The Real Cost of Non-Compliance
Financial Penalties
The TGA continues to actively investigate businesses promoting prescription-only medicinal cannabis to the public. In 2024, the regulator issued 35 infringement notices totalling more than $627,000 across multiple businesses for alleged unlawful advertising. The alleged breaches included:
Advertising prescription-only medicinal cannabis;
Making prohibited therapeutic claims;
Using indirect terms such as "plant medicine";
Promoting products directly to consumers; and
Implying TGA approval where none existed.
In 2025, another medicinal cannabis business received six infringement notices totalling $118,800, together with a direction to cease the alleged unlawful advertising. While these infringements impact a business’s bottom line, financial penalties are just the beginning. The true cost of non-compliance often lies in reputational damage.
Reputational Damage
Reputation is one of the most valuable assets in any industry. When compliance action becomes public; patients, prescribers, pharmacies, investors and commercial partners inevitably question whether they can trust the organisation. Rebuilding confidence often takes years—and may cost substantially more than implementing appropriate compliance systems in the first place.
Lost Commercial Opportunities
Non-compliant businesses frequently experience:
Delayed commercial partnerships;
Increased due diligence from investors;
Difficulties securing distribution agreements;
Slower patient adoption;
Increased legal costs; and
Management distraction during regulatory investigations.
These hidden costs often exceed the value of regulatory penalties.
Compliance Creates Competitive Advantage
The organisations that will succeed in Australia’s medicinal cannabis market over the next decade will be the businesses that build trust through:
Robust governance;
Compliant commercial strategies;
Evidence-based education;
Ethical engagement with healthcare professionals;
Operational excellence; and
Ongoing long-term regulatory compliance.
Strong compliance demonstrates professionalism and gives confidence to regulators, healthcare practitioners, investors and patients alike.
How EQWELLIBRIYUM Helps
At EQWELLIBRIYUM, we work alongside medicinal cannabis brands, clinics, wholesalers and healthcare organisations to help them grow confidently within Australia’s evolving regulatory environment.
Our team combines commercial expertise with practical industry knowledge to support businesses across:
Market entry strategy
Operational optimisation
Commercial growth
Sales forecasting & advice
Medical education
Marketing strategy
Wholesale and distribution
Industry partnerships
Regulatory compliant business development
Rather than treating compliance as an obstacle, we help organisations integrate compliance into commercial strategy—supporting sustainable growth while protecting their reputation. As regulatory scrutiny continues to increase, organisations that invest in compliance today will be better positioned to lead tomorrow.
Learn more about how EQWELLIBRIYUM can help your business navigate Australia’s medicinal cannabis market by contacting us directly at hello@eqwellibriyum.com
References
Compliance actions and outcomes. Australian Government Department of Health and Aged Care.
Therapeutic Goods Administration. Medicinal Cannabis News and Updates.
Federal Register of Legislation, Therapeutic Goods Act 1989.